Massachusetts Society of Clinical Oncologists - FDA approves sacituzumab govitecan-hziyv (Trodelvy) for HR-positive breast cancer

"The voice for cancer physicians and their patients in Massachusetts."

Home
Resources
For Professionals
FDA Approvals
FDA approves sacituzumab govitecan-hziyv (Trodelvy) for HR-positive breast cancer

FDA approves sacituzumab govitecan-hziyv (Trodelvy) for HR-positive breast cancer

06 Feb 2023 1:22 PM | Katy Monaco (Administrator)

Food and Drug Administration (FDA) approved sacituzumab govitecan-hziy (Trodelvy, Gilead Sciences, Inc.) for patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. Read More.

View full prescribing information for Trodelvy.

860 Winter Street, Waltham, MA, 02451
Tel: 781.434.7329 | email: msco@mms.org